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Activating K-Ras mutations occurs frequently in
pancreatic cancers and is implicated in their devel-
opment. Cancer-initiating events, such as oncogenic
Ras activation, lead to the induction of cellular senes-
cence, a tumor suppressor response. During senes-
cence, the decreased levels of KDM4A lysine deme-
thylase contribute to p53 activation, however, the
mechanism bywhich KDM4A is downregulated is un-
known. We show that miR-137 targets KDM4A
mRNA during Ras-induced senescence and acti-
vates both p53 and retinoblastoma (pRb) tumor sup-
pressor pathways. Restoring the KDM4A expression
contributed to bypass of miR-137-induced senes-
cence and inhibition of endogenous miR-137 with
an miRNA sponge-compromised Ras-induced
senescence.miR-137 levels are significantly reduced
in human pancreatic tumors, consistent with previ-
ous studies revealing a defective senescence
response in this cancer type. Restoration of miR-
137 expression inhibited proliferation and promoted
senescence of pancreatic cancer cells. These results
suggest that modulating levels of miR-137 may be
important for triggering tumor suppressor networks
in pancreatic cancer.INTRODUCTION
Escape from oncogene-induced senescence (OIS) potentiates
malignant transformation. In human fibroblasts, defects in the
ARF/p53 and p16INK4A/pRb tumor suppressor pathways are
required to bypass OIS (Lowe et al., 2004). Not surprisingly,
therefore, these pathways are frequently altered in Ras-driven
cancers, since hyperactivation of Ras triggers p53- and pRb-
dependent OIS and growth inhibition in normal cells (Serrano1966 Cell Reports 14, 1966–1978, March 1, 2016 ª2016 The Authorset al., 1997). OIS represents a critical tumor-suppressive mech-
anism in vivo (Braig et al., 2005; Chen et al., 2005; Collado et al.,
2005; Kuilman et al., 2010; Michaloglou et al., 2005). In untrans-
formed cells, sustained MAP kinase signaling induced by acti-
vated Ras leads to senescence, i.e., permanent G1 arrest (Lin
et al., 1998; Serrano et al., 1997; Zhu et al., 1998). During onco-
genic stress, p53 stimulates many genes that promote cellular
senescence, including those encoding the CDK inhibitor
p21cip/waf1 (hereafter p21) (Lowe et al., 2004), the promyelocytic
leukemia (PML) protein (Pearson et al., 2000), and plasminogen
activator inhibitor type 1 (PAI-1, Kunz et al., 1995). p21 mediates
G1/S arrest by inhibiting G1 cyclin-dependent kinases (McCon-
nell et al., 1998). PML recruits p53 to nuclear bodies to stimulate
transcription of p53 targets, including p53 itself (de Stanchina
et al., 2004; Ferbeyre et al., 2000). The product of the alternative
reading frame of the INK4A/ARF locus, p19ARF, also is induced
by oncogenes (Lowe and Sherr, 2003). p19ARF sequesters
MDM2 to the nucleolus, which in turn protects p53 from
MDM2-associated proteasomal degradation (Weber et al.,
1999). Expression of oncogenes also leads to upregulation of
the CDK inhibitor p16INK4A (Gan et al., 2008; Lin et al., 1998), in
turn blocking inhibitory phosphorylation of pRb (Ruas and Pe-
ters, 1998) and of consequent (Chellappan et al., 1991; Nevins
et al., 1991) E2F-dependent transcription of genes required for
G1/S progression (Chicas et al., 2010).
The K-Ras member of the Ras GTPase family is mutated in
>95% of pancreatic ductal adenocarcinoma (PDAC) (Stephen
et al., 2014), and the INK4A/ARF and TP53 loci are mutated in
80% of such cases. Moreover, such mutations are associated
with the more malignant and aggressive forms of PDAC (Moir
et al., 2014). Re-establishment of p53 in K-Ras-driven tumors
leads to tumor regression in vivo (Dickins et al., 2005), while
restoration of p16INK4A in K-Ras-driven pancreatic cancer cells
inhibits clonogenic proliferation (Rabien et al., 2012), further indi-
cating the crucial roles of p53 and p16INK4A in pancreatic tumor
suppression.
The precise molecular basis for activation of the ARF/p53 and
p16INK4A/pRb pathways duringOIS remains unclear.We recently
reported the reduction of KDM4A lysine demethylase (also
known as JMJD2A) levels upon Ras activation, which in turn
stimulates expression of the CHD5 tumor suppressor; further-
more, overexpression of KDM4A in p16INK4A-depleted fibro-
blasts led to bypass of OIS (Mallette and Richard, 2012). In addi-
tion KDM4A cooperated with Ras in the transformation of
primary cells by inhibiting the p53 pathway, suggesting that
KDM4A depletion following oncogenic signaling modulates
p53 activation.
KDM4A catalyzes the removal of di- and tri-methylated lysines
9 and 36 of histone H3 (H3K9/H3K36) via a dioxygenase reaction
mechanism (Tsukada et al., 2006; Whetstine et al., 2006).
KDM4A possesses a JmjC catalytic domain and its catalytic ac-
tivity is dependent on Fe2+ and a-ketoglutarate (Tsukada et al.,
2006). This demethylase participates in multiple processes,
including the DNA damage response (Mallette et al., 2012),
gene amplification (Black et al., 2013), the immune response
(Jin et al., 2014), and the transcriptional activation of p53 (Mal-
lette and Richard, 2012). Chromatin immunoprecipitation
(ChIP) experiments revealed binding of KDM4A to promoter re-
gions of ASCL2 (Zhang et al., 2005), CHD5, PANX2, and PPIC
(Mallette and Richard, 2012). In KDM4A-depleted cells, the
p53 response is activated as assessed by the nuclear transloca-
tion of p53 and the increased expression of p53 targets, such as
p21 and PML (Mallette and Richard, 2012). Initially identified as a
tumor suppressor gene in neuroblastoma (Thompson et al.,
2003), CHD5 was later found to block tumorigenesis in vivo by
positively regulating the INK4A/ARF locus (Mallette and Richard,
2012). Furthermore, loss ofCHD5was shown to inhibit OIS (Bag-
chi et al., 2007). Following transcriptional repression of CHD5,
KDM4A can counteract CHD5-dependent activation of the p53
pathway during Ras-induced senescence (Mallette and Richard,
2012). Decreased KDM4A expression following oncogenic stim-
ulation seems to be a crucial determinant of OIS, but the mech-
anism responsible for KDM4A downregulation remains elusive.
Several studies have revealed emerging roles for microRNAs
(miRNAs) in the regulation of cellular senescence. miR-372 and
miR-373 were characterized as oncogenic miRNAs collabo-
rating with Ras through suppression of LATS2, an intermediate
of p53-mediated CDK inhibition (Voorhoeve et al., 2006).
Furthermore, the miR-17-92 gene cluster promotes malignant
transformation, and miR-37/20a encoded within this cluster
can bypass OIS (Hong et al., 2010). Conversely, increased Ras
expression was correlated with Let-7 depletion in lung cancer
(Johnson et al., 2005), suggesting that miRNAs also can exert tu-
mor-suppressive functions. In addition, p53 was shown to acti-
vate transcription, and maturation, of several miRNAs involved
in cell-cycle arrest and senescence (Feng et al., 2011).
Herein we show that miR-137 targets KDM4A during Ras-
induced senescence, leading to activation of the p53/pRb tumor
suppressor pathways. Ectopic expression of miR-137 was suffi-
cient to stimulate senescence in a p53- and pRb-dependent
manner. Inactivation of miR-137 compromised Ras-induced
senescence and decreased p21 mRNA levels. Finally, miR-137
levels were significantly reduced in human pancreatic tumors,
and its re-expression induced cellular senescence in PANC1
cells. These findings suggest that the modulation of miR-137/
KDM4A regulation may have therapeutic value in pancreatic
cancer.CeRESULTS
Identification of miR-137 as a Regulator of KDM4A
KDM4A protein levels are decreased during Ras-induced senes-
cence, thereby relieving the CHD5 promoter from negative regu-
lation and allowing increased p53 expression (Mallette and Ri-
chard, 2012). In addition, KDM4A mRNA is significantly
reduced during OIS, while the levels of KDM4B and KDM4C pa-
ralogs remain unchanged (Figure 1A), suggesting that dimin-
ished KDM4A activity may contribute to OIS. Indeed, KDM4A
depletion using small interfering RNAs (siRNAs) induced prema-
ture senescence (Figures S1A and S1B) associated with an
increase inCHD5mRNA levels (Figure S1C), consistent with pre-
vious findings (Mallette and Richard, 2012). However, themolec-
ular mechanism responsible for the downregulation of KDM4A
during OIS remains to be elucidated.We hypothesized that mod-
ulation of miRNA activity might be responsible for downregula-
tion of KDM4A during OIS. Using miRANDA (http://www.
microrna.org/microrna/home.do) and TARGETSCAN (http://
www.targetscan.org/) algorithms (Enright et al., 2003; Lewis
et al., 2003), we identified miR-137, miR-145, and miR-220c as
predicted to target the 30 UTR of KDM4A (Figures 1B and 1C).
Interestingly, miR-137 and miR-145 are downregulated in
various cancer types, suggesting that they may function as tu-
mor suppressors (Bemis et al., 2008; Iorio et al., 2005; Kozaki
et al., 2008; Nilsson et al., 2015; Silber et al., 2008).
To examine whether miR-137, miR-145, and/or miR-220c
regulate KDM4A levels during OIS, we first measured levels of
these miRs using qRT-PCR in senescent IMR90 normal diploid
lung fibroblasts expressing H-RasV12. Mature miR-137 levels
significantly increased, while miR-145 decreased and miR-
220c levels did not change in H-RasV12-expressing cells (Fig-
ure 1D). We also documented a substantial increase (2-fold)
in miR-137 levels as early as 1 day after Ras induction, concom-
itant with a decrease of KDM4A mRNA levels (>2-fold; Fig-
ure S2A). KDM4A mRNA seemed to be stabilized at day 1
post-H-RasV12 induction, while miR-137 expression progres-
sively increased >5-fold after 5 days (Figure S2A).
Since miR-137 was the only KDM4A-targeting candidate
miRNA whose expression increased during OIS, we focused
on the role of this miRNA. To evaluate its potential effect on
KDM4A, we overexpressed mature miR-137 levels in IMR90 fi-
broblasts using miRNA mimics. The relative levels of KDM4A
mRNA and a previously described miR-137 target, CDC42 (Liu
et al., 2011), were significantly reduced relative to miR-67 (Fig-
ure 1E), a Caenorhabditis elegans-specific miRNA (Sharma
et al., 2009). The mRNA level of CHD5, a transcriptional target
of KDM4A (Mallette and Richard, 2012), was increased following
transfection with miR-137, consistent with decreased KDM4A
mRNA expression and protein levels (Figure 1E).
The reduced level of KDM4A protein was confirmed subse-
quently by immunoblotting in U2OS and IMR90 fibroblasts (Fig-
ure 1F), and p53 protein was increased upon miR-137 treatment
(Figure 1F), consistent with the increase in the p53-positive regu-
lator CHD5 (Mallette and Richard, 2012; Thompson et al., 2003).
The KDM4A 30 UTR harbors two miR-137 seed sequences that
we termed miR-137 response elements (MREs) 1 and 2 (Figures
1B and 1C; MRE1 and MRE2). Renilla luciferase reporter genesll Reports 14, 1966–1978, March 1, 2016 ª2016 The Authors 1967
Figure 1. KDM4A Is a Target of Ras-Induced
miR-137
(A) The mRNA expression levels of the KDM4
family members were quantified by real-time qRT-
PCR during Ras-induced senescence in IMR90
fibroblasts. The values were normalized to
GAPDH. The significance was measured by the
Student’s t test and defined as **p < 0.01 or n.s.,
non-significant (n = 3).
(B) The sequence of the miRNA-binding sites in the
KDM4A 30 UTR is shown, as predicted by
miRANDA and TARGETSCAN algorithms.
(C) Schematic representations of the relative po-
sitions of putative miRNAs targeting the KDM4A 30
UTR. The two miR-137 response elements (MREs)
shown are not drawn to scale.
(D) Detection of the levels of miR-137, miR-145,
and miR-220c by real-time qRT-PCR during Ras-
induced senescence in IMR90 fibroblasts. The
values were normalized to U6 small nuclear RNA
(snRNA). The significance was measured by the
Student’s t test and defined as *p < 0.05; **p <
0.01; or n.s., non-significant (n = 3).
(E) Primary diploid human fibroblasts IMR90
fibroblasts were transfected twice with 20 nMmiR-
67 or miR-137miRNAmimic within a 3-day interval
and kept in culture for 8 days. (Left) The mRNA
expression of KDM4A, CHD5, and CDC42 was
quantified by real-time qRT-PCR and normalized
to the geometric mean of ACTB and GAPDH, as
decribed by Vandesompele and colleagues (Van-
desompele et al., 2002). The significance was
measured by the Student’s t test and defined as
*p < 0.05 or **p < 0.01 (n = 3). (Right) Total cell ly-
sates were immunoblotted with anti-KDM4A and
anti-b-actin antibody was used to control for
equivalent loading. Western blots are representa-
tive of three independent experiments.
(F) U2OS and IMR90 cells were transfected with
either 100 nM miR-67 or miR-137 for 3 days. Total
cell lysates were immunoblotted with anti-KDM4A,
anti-p53 antibodies. Anti-a-tubulin antibody was
used to control for equivalent loading. Western
blots are representative of three independent ex-
periments.
(G) HEK293T cells were transfected with 50 nM miR-67 or miR-137 miRNA mimic. The next day, cells were co-transfected with firefly luciferase plasmid and a
Renilla luciferase reporter vector harboring either 5 BoxB sequences (5BoxB), wild-type humanMRE1 orMRE2, or mutated versions. Data were normalized to the
expression of the 5BoxB vector and expressed as the ratio of Renilla/firefly signals. Results shown are representative of three independent experiments. The
significance was measured by the Student’s t test and defined as *p < 0.05 or n.s., non-significant.
See also Figures S1 and S2.harboring either wild-type human MRE1 or MRE2 or mutated
versions were generated and transfected in HEK293T cells along
with miR-137 and a firefly luciferase plasmid to control for trans-
fection efficiency; pCI-RL:MRE2 was sensitive to miR-137
expression, while pCI-RL:MRE1 was not (Figure 1G). Mutation
of the MRE2 seed sequence rendered it insensitive to miR-
137, whereas no change was observed with mutated MRE1 (Fig-
ure 1G). These findings suggest that miR-137 mainly targets
MRE2 located from 4,471 to 4,492 (Figure 1G). KDM4A mRNA
decay experiments using IMR90 cells stably expressing H-
RasV12 fused to an estrogen receptor ligand-binding domain
(ER:RASV12) (Young et al., 2009) revealed that the half-life of
the KDM4A mRNA is not affected by the establishment of the1968 Cell Reports 14, 1966–1978, March 1, 2016 ª2016 The Authorssenescence phenotype (Figure S2B). These observations sug-
gest that miR-137 negatively regulates KDM4A primarily through
translational repression rather than mRNA levels, leading to the
subsequent stimulation of the CHD5/p53 axis.
miR-137 Induces Senescence
We next postulated that miR-137 may promote senescence
through the downregulation of KDM4A, and we evaluated this
hypothesis by transfecting IMR90 normal human fibroblasts
with an miR-137 mimic. A robust senescence response was
observed upon transfection of miR-137 compared to miR-67-
transfected cells, as assessed using senescence-associated
b-galactosidase activity (SA-b-gal; Figure 2A; 40% versus
Figure 2. miR-137 Induces Cellular Senes-
cence
(A) IMR90 fibroblasts were transfected with miRNA
mimics and stained for SA-b-gal. Representative
images are shown on the left and quantification is
shown on the right. Themean percentage and SDof
SA-b-gal-positive cells indicated in the right panel
are representative of three independent experi-
ments with >100 cells per experiment. The signifi-
cance was measured by the Student’s t test and
defined as **p < 0.01.
(B) Indirect immunoflurorescence of PML and
gH2AX of cells prepared as in (A). The nuclei were
counterstained with DAPI. Representative images
are shown on the left and quantification is shown on
the right. Themean percentage and SD of cells with
more than ten foci indicated in the right panel are
representative of three independent experiments,
with >100 cells per experiment. The significance
was measured by the Student’s t test and defined
as **p < 0.01.
(C) Quantification by real-time qRT-PCR of the
levels of p53 and E2F target genes of IMR90 fi-
broblasts described in (A). The values were
normalized to the geometric mean of ACTB and
GAPDH. The significance was measured by the
Student’s t test and defined as *p < 0.05 or **p <
0.01 (n = 3).
(D) IMR90 fibroblasts expressing empty vector, or
FLAG-tagged KDM4A lacking the 30 UTR, were
transfected with miRNA mimic and stained for SA-
b-gal. Representative images are shown on the left
and quantification is shown on the right. The mean
percentage and SD of SA-b-gal-positive cells indi-
cated in the right panel are representative of three
independent experiments with >100 cells per
experiment. The significance was measured by the
Student’s t test and defined as **p < 0.01.12%). Subsequently, an increase in the number of PML nuclear
bodies and gH2AX foci, two known markers of cells undergoing
cellular senescence (Ferbeyre et al., 2000; Mallette et al., 2007),
also were observed in miR-137-expressing cells (Figure 2B).
We next examined whether miR-137 leads to the activation of
the ARF/p53 and p16INK4A/pRb pathways by qRT-PCR. The
mRNA of several p53 targets, such as PAI-1, GADD45A,
MDM2, CDKN1A, and PML, were increased in miR-137-trans-
fected cells, but not in miR-67-transfected cells (Figure 2C).
The expression of an E2F-responsive gene, CDC2, was signifi-
cantly decreased upon miR-137 expression, consistent with
the activation of the pRb pathway (Figure 2C). These observa-
tions show that miR-137 promotes premature senescence in
normal human diploid fibroblasts and engages both ARF/p53
and p16INK4A/pRb tumor suppressor pathways.
To test whether miR-137 induces senescence by depleting
KDM4A, we reintroduced a miR-137-insensitive wild-type
FLAG-tagged KDM4A variant into miR-137-transfected fibro-
blasts. The KDM4A expression vector carries the codingCell Reports 14, 1966–19sequence, but it lacks the 30 UTR con-
taining the miR-137 complementary se-
quences and is, therefore, insensitive tomiR-137. The expression of wild-type KDM4A partially rescued
the miR-137-induced senescence phenotype, as assessed by
SA-b-gal staining (Figure 2D; 16% versus 36%).
miR-137 Triggers Both ARF/p53- and p16INK4A/pRb-
Dependent Pathways
The establishment of senescence in normal human fibroblasts
involves both the p53 and the p16INK4A tumor suppressor path-
ways (Ferbeyre et al., 2000; Mallette et al., 2007; Serrano et al.,
1997). Since the expression of KDM4A could not completely
rescue the senescence phenotype induced by miR-137 (Fig-
ure 2D), we proposed that miR-137 also could trigger senes-
cence in a p53-independent manner, through the p16INK4A
pathway. To verify which pathway(s) is targeted by miR-137,
we transfected miR-137 mimic into fibroblasts where p53 or
p16INK4A was depleted. Transfection of miR-137 mimic in
sh_GFP control cells induced senescence in 39% of the cell
population, as shown by increased SA-b-gal-positive cells (Fig-
ure 3A). Interestingly, we observed that inhibition of either the78, March 1, 2016 ª2016 The Authors 1969
p53 or p16INK4A pathway separately was insufficient to
completely block senescence induced by miR-137 (Figure 3A).
This was further confirmed using additional hallmarks, such as
increased PML bodies and gH2AX foci in sh_p16 or sh_p53 cells
transfected with miR-137 (Figures 3B and 3C). A slight reduction
in the number of PML bodies was observed in sh_p53-express-
ing cells as expected, since PML is a direct transcriptional target
of p53 (de Stanchina et al., 2004). These findings suggest that
ectopic expression of miR-137 does not exclusively activate
p53 signaling via decreased KDM4A levels, but also engages
the p16INK4A pathway.
To confirm that miR-137 triggers senescence by simulta-
neously activating the p53 and p16INK4A pathways, we ex-
pressed the human papilloma viral proteins E6 and E7 known
to inhibit the p53 and pRb pathways, respectively (Shay et al.,
1991). E6 promotes the proteasomal degradation of p53 (Maki
et al., 1996; Scheffner et al., 1990), while E7 interferes with
pRb by blocking its ability to repress E2F-dependent gene
expression (Roman and Munger, 2013). Expression of human
papilloma viral E6 and E7 in miR-137-transfected fibroblasts fully
rescued the senescence phenotype, suggesting that miR-137
indeed relies on either the p53 or p16INK4A pathway to establish
senescence (Figure 3D). Similarly, as shown in Figures 2D and
3A, miR-137-induced senescence was partially rescued in
sh_p16- or KDM4A-expressing fibroblasts, while concomitant
inhibition of p16INK4A and expression of KDM4A led to a com-
plete block of miR-137-induced senescence (Figure 3E). These
data confirm that miR-137 engages a tumor suppressor network
involving p53 and pRb pathways to promote cellular
senescence.
miR-137 Loss of Function Blocks Ras-Induced
Senescence
To determine the functional significance of miR-137 induction
during OIS, we used a lentiviral vector encoding an antisense
sequence to mature miR-137 (miR-OFF-137) (Cheng et al.,
2005) to inhibit its activity. We validated the inhibitory effect of
miR-OFF-137 in IMR90 cells transfected with the MRE2 Renilla
luciferase reporter. The presence of miR-OFF-137, but not
miR-OFF-CTRL, led to an increase of20-fold in Renilla activity,
consistent with decreased miR-137 function (Figure 4A). We
then transduced miR-OFF-137 in ER:RASV12-expressing
IMR90 fibroblasts, and we observed a senescence bypass after
9 days of Ras induction by OHT treatment, as revealed by a
significantly lower number of SA-b-gal-positive cells and a char-
acteristic flat, vacuolated cytoplasm compared to miR-OFF-
CTRL-expressing cells (15% versus 53%; Figures 4B and
4C). Transcriptional activation of CDKN1A also was compro-
mised in miR-137-inhibited cells after the induction of oncogenic
Ras, as quantified by qRT-PCR, consistent with p53 activation
(Figure 4D). These results show that inhibiting endogenous
miR-137 expression in IMR90 cells prevents Ras-induced
senescence.
DNA Damage Induces miR-137 Expression
DNA damage is an important instigator of cellular senescence in
primary cells (Bartkova et al., 2006; Mallette et al., 2007). To
define the mechanism regulating the expression of miR-137,1970 Cell Reports 14, 1966–1978, March 1, 2016 ª2016 The Authorswe monitored its levels following DNA damage. Stimulation of
the DNA damage response by doxorubicin led to a significant in-
crease in miR-137 (Figure 5A) and a decrease in KDM4A mRNA
levels (Figure 5B). As p53 transcriptional activity is stimulated af-
ter DNA damage, we next examined whether expression of miR-
137 required p53. IMR90 cells expressing a small hairpin RNA
(shRNA) targeting p53 exhibited decreased levels of miR-137,
as well as the classical p53 target gene CDKN1A, although
GAPDH expression levels were unaffected (Figure 5C). Taken
together, these data suggest that miR-137 expression is stimu-
lated by DNA damage and requires p53.
Pancreatic Cancer Exhibits Lower Levels of miR-137
K-Ras is activated by somatic mutations in a majority of human
pancreatic cancers (Stephen et al., 2014). We have shown here
that miR-137 is induced in normal cells expressing RasV12 and
following DNA damage (Figures 1D, S2A, and 5A), and it stimu-
lates a tumor suppressor network involving the p53 and
p16INK4A pathways. Therefore, we compared the relative levels
of miR-137 in pancreatic tumor versus normal tissues. Analysis
of tissue microarray expression data from Pei and coworkers
(Pei et al., 2009), gathering gene expression profiles of 36
pancreatic tumor and 16 normal tissue samples (GEO:
GSE16515), revealed significant decreased expression of miR-
137 in pancreatic tumors compared to normal tissues, but not
KDM4A mRNA levels (Figure 6A). We then compared the abso-
lute amount of endogenous miR-137 in normal diploid IMR90 fi-
broblasts as well as in the K-Ras-mutated pancreatic cell line
PANC-1. We observed that IMR90 fibroblasts contain 55
copies of miR-137 per cell, while miR-137 was undetectable in
PANC-1 cells (Figure S3). We therefore examined the relation-
ship between the expression of miR-137 in tumor samples and
KDM4A and KDM4A’s target genes (Mallette and Richard,
2012; Zhang et al., 2005). The expression of miR-137 in pancre-
atic tumor tissues correlated with levels of KDM4A-repressed
genes CHD5, ASCL2, and PANX2, displaying coefficients of
determination r2 of 0.7810, 0.7874, and 0.4068, respectively (Fig-
ure 6B). The miR-137 expression also correlated with the
KDM4A-stimulated target gene PPIC (Mallette and Richard,
2012), with a coefficient of determination r2 of 0.2018 (Figure 6B).
We did not observe a correlation between miR-137 and KDM4A
mRNA (r2 = 0.04611), nor did we observe a correlation between
miR-137 and two of its own targets, CDK6 and CDC42 (r2 of
0.01059 and 5.147E5, respectively; Figure 6C). These findings
suggest that there is a correlation between miR-137 and
KDM4A’s target genes.
Restoration of miR-137 in Pancreatic Cancer Cells
Causes Cellular Senescence
Wehave shown that oncogenicRas signaling increasedmiR-137
levels and that it contributes to the establishment of the senes-
cence program in normal human diploid cells. Since miR-137
expression is reduced in pancreatic tumors (Figures 6A and
6B), as well as absent in PANC-1 cells (Figure S3), we restored
miR-137 expression in pancreatic tumor cells to determine if
this can trigger cellular senescence. The expression of
miR-137 in PANC-1 significantly decreased the growth rate (Fig-
ure 6D) and induced cellular senescence (Figure 6E).
Figure 3. miR-137 Engages Both the p53 and p16INK4A Tumor Suppressor Pathways
(A) IMR90 fibroblasts expressing sh_GFP, sh_p53, or sh_p16 were transfected with miRNA mimic and fixed for SA-b-gal staining. Representative images are
depicted in the top panel and the quantification is below. Themean percentage and SD of SA-b-gal-positive cells indicated in the bottom panel are representative
of three independent experiments with >100 cells per experiment. The significance was measured by the Student’s t test and defined as *p < 0.05 or **p < 0.01.
(B and C) Indirect immunofluorescence against PML bodies or gH2AX foci in cells as prepared in (A). The nuclei were counterstained with DAPI. Representative
images are shown on the left and quantification is shown on the right. Themean percentage and SD of cells with more than ten foci indicated in the right panel are
representative of three independent experiments and expressed as SD of the mean, with >100 cells per experiment. The significance was measured by the
Student’s t test and defined as *p < 0.05 or **p < 0.01.
(D) IMR90 fibroblasts infected with empty or E6/E7-expressing vector were transfected with miRNA mimic and stained for SA-b-gal. Representative images are
depicted in the top panel and the quantification is below. The mean percentage and SD of SA-b-gal-positive cells indicated on the bottom panel are
(legend continued on next page)
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Figure 4. miR-137 Loss of Function Blocks Ras-Induced Senescence
(A) IMR90 fibroblasts were transduced with miR-OFF-CTRL or miR-OFF-137 inhibitor vector and transfected either with 5BoxB or MRE2 Renilla luciferase re-
porter described in Figure 1G. Firefly luciferase vector was used as a transfection control. Data were normalized to the expression of the 5BoxB vector and
expressed as the ratio of Renilla/firefly signals. Results shown are representative of four independent experiments. The significance was measured by the
Student’s t test and defined as **p < 0.01.
(B) IMR90 fibroblasts co-expressing ER:RASV12 and miR-OFF-CTRL or miR-OFF-137 inhibitor vector were either supplemented with ethanol or 100 nM OHT for
9 days. Cells were fixed for SA-b-gal staining. Representative images of three independent experiments are shown.
(C) Quantification of SA-b-gal-positive cells in (B). The mean percentage and SD of SA-b-gal-positive cells indicated on the right panel are representative of three
independent experiments with >100 cells per experiment. The significance was measured by the Student’s t test and defined as **p < 0.01.
(D) Quantification by real-time qRT-PCR of the levels of CDKN1A in cells described in (B). The values were normalized to the geometric mean of ACTB and
GAPDH. The significance was measured by the Student’s t test and defined as *p < 0.05 (n = 3).Comparable results were obtained with siRNA-mediated knock-
down of KDM4A in PANC-1 cells (Figures S4A and S4B), sug-
gesting the possible contribution of KDM4A depletion in trig-
gering senescence of PANC-1 cells. These observations show
that miR-137-induced senescence can be restored in PANC-1,
thus blocking their proliferation.representative of three independent experiments with >100 cells per experiment. T
or n.s., non-significant.
(E) IMR90 fibroblasts co-expressing sh_GFP or sh_p16 and empty vector or FLAG
Representative images are depicted in the top panel and the quantification is be
bottom panel are representative of three independent experiments with >100 ce
defined as *p < 0.05; **p < 0.01; or n.s., non-significant.
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In this paper, we describe the ability of miR-137 to induce cellular
senescence. miR-137 levels are increased during OIS and in
response to DNA damage. Ectopic expression of miR-137 led
to a cell-cycle arrest phenotype associated with the hallmarkhe significancewasmeasured by the Student’s t test and defined as **p < 0.01
-tagged-KDM4Awere transfected with miRNAmimic and stained for SA-b-gal.
low. The mean percentage and SD of SA-b-gal-positive cells indicated on the
lls per experiment. The significance was measured by the Student’s t test and
Figure 5. DNA Damage Induces miR-137
(A) Quantification by real-time qRT-PCR of the levels of miR-137 after 16-hr
treatment with 1 mMdoxorubicin of U2OS cells. The values were normalized to
U6 snRNA. The significance was measured by the Student’s t test and defined
as *p < 0.05 (n = 3).
(B) The mRNA expression levels of the KDM4 family members quantified by
real-time qRT-PCR during DNA damage response from cells described in (A).
The values were normalized to ACTB mRNA. The significance was measured
by the Student’s t test and defined as *p < 0.05 or n.s., non-significant (n = 3).
(C) RNA from IMR90 fibroblasts infected with either sh_GFP- or sh_p53-ex-
pressing vector was extracted and analyzed by real-time qRT-PCR. mRNA
levels of CDKN1A and GAPDH were normalized to ACTB, while mature miR-
137 levels were normalized to U6 snRNA. The significance was measured by
the Student’s t test and defined as *p < 0.05 or **p < 0.01 (n = 3).of premature cellular senescence.We demonstrate that miR-137
engages both ARF/p53 and p16INK4A/pRb pathways to promote
cellular senescence, and we have identified the mRNA of the
KDM4A lysine demethylase as an miR-137 target. KDM4A previ-
ously was shown to decrease during OIS and its restoration al-
lowed bypass of cellular senescence (Mallette and Richard,
2012). We now show that downregulation of KDM4A by miR-
137 activates the CHD5/p53 tumor suppressor pathway. In addi-
tion, expression of an miRNA-insensitive KDM4A partially
rescuedmiR-137-induced senescence, while a complete rescue
was achieved with the concomitant expression of KDM4A and
depletion of p16INK4A, consistent with miR-137 engaging both
ARF/p53 and p16INK4A/pRb pathways. Inhibition of endogenous
miR-137 using an miRNA sponge in IMR90 severely compro-
mised the OIS response and engendered a significant decrease
of CDKN1A expression, thus confirming the contribution of
miR-137 in the activation of p53 and establishment of cellular
senescence. In human pancreatic tumors, we show that the
expression of three transcriptional targets repressed by
KDM4A, CHD5, ASCL2, and PANX2, correlated with miR-137Ceexpression levels. This observation suggests that miR-137, by
decreasing KDM4A levels, relieved KDM4A-mediated repres-
sion on these genes. Ectopic expression of miR-137 in pan-
creatic cancer cell line PANC-1 halted cell proliferation and
induced cellular senescence, a cellular response also observed
upon the depletion of KDM4A. These findings suggest that
increasing miR-137 in pancreatic cancer might be of therapeutic
significance.
Reduced expression levels of mature miR-137 has been re-
ported in many tumor types including glioblastoma (Chen
et al., 2012) and ovarian cancer (Guo et al., 2013), and also
Ras-driven colorectal cancer (Chen et al., 2013), non-small cell
lung carcinoma (Zhang et al., 2015), and prostate cancer (Nilsson
et al., 2015). Furthermore, miR-137 was shown to reduce inva-
sion while increasing sensitivity to chemotherapy in pancreatic
cancer (Xiao et al., 2014). We now define the molecular mecha-
nism of action ofmiR-137. In this respect, we have defined herein
the molecular underpinnings by showing that miR-137 stimu-
lates a tumor suppressor network engaging both ARF/p53 and
p16INK4A/pRb pathways to promote cellular senescence in
pancreatic cancer cells. Taken together, our data also suggest
that the ability of miR-137 to induce senescencemay be relevant
to many cancer types.
Activation of the DNA damage response is known to stimulate
the maturation of specific miRNAs (Chowdhury et al., 2013). We
show that the expression of miR-137 is induced by DNA dam-
age, and further experimentation is required to define whether
miR-137 is a direct target of p53. Attempts to identify chro-
matin-bound p53 at putative p53 response elements in the
miR-137 upstream region by ChIP were unsuccessful (data not
shown). It is possible that we have not identified the appropriate
p53-binding site. p53 has been shown to stimulate the matura-
tion of numerous miRNAs (Suzuki et al., 2009), and this also
may be a mechanism by which miR-137 is regulated by p53.
Thus, we have uncovered a mechanism whereby miR-137 and
p53 promote each other’s activation in a positive feedback
loop during the DNA damage response and following oncogenic
stress (see model Figure 7).
PDAC is the most frequent form of pancreatic cancer (90%
of the cases), is highly aggressive, and exhibits a very poor 5-
year survival rate (<5%) (Bryant et al., 2014; Eser et al., 2014).
Activating K-Ras mutations is recognized as a primary determi-
nant in the initiation of pancreatic intraepithelial neoplasia
(PanIN) (Eser et al., 2014), however, progression from low-grade
PanIN to PDAC often requires the chronological disruption of the
INK4A/ARF tumor suppressor locus followed by p53 inactivation
(Hezel et al., 2006), leading to genomic instability and tumor pro-
gression (Bryant et al., 2014; Hezel et al., 2006). miR-137 expres-
sion is decreased in pancreatic tumors, and its restoration in
PANC-1 cells induced cellular senescence response and growth
inhibition. Accordingly, downstream miR-137 signaling seems
intact and functional in pancreatic cancers. Additionally, bypass
of OIS observed upon miR-137 loss of function greatly supports
the notion that the loss of miR-137 is an early event driving
pancreatic tumorigenesis in cooperation with activated Ras.
We observed that miR-137 levels are lower in a pancreatic tu-
mor tissue cohort versus normal tissues. miR-137 expression
correlated with levels of KDM4A downstream negative targetsll Reports 14, 1966–1978, March 1, 2016 ª2016 The Authors 1973
Figure 6. Restoration of miR-137 in Pancreatic Cancer Cells Induced Premature Senescence
(A) Levels of miR-137 and the KDM4A mRNA in normal and pancreatic tumor tissues were obtained from Affymetrix Human Genome U133 Plus 2.0 Array data.
The significance was measured by the Student’s t test and defined as *p < 0.05.
(B) Scatterplot showing correlation between the relative expression of endogenous miR-137 levels and KDM4A negative mRNA targets CHD5, ASCL2, and
PANX2 or KDM4A-positive target PPIC from the tumor samples described in (A). The coefficient of determination r2 is shown adjacent to the linear regression
curve.
(C) KDM4A, CDK6, and CDC42 were plotted as described in (B). The coefficient of determination r2 is shown adjacent to the linear regression curve.
(D) Growth curve of PANC-1 cells transfected with 50 nM siGFP or miR-137 mimic is shown.
(legend continued on next page)
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Figure 7. Model of Senescence Induction by
miR-137 following OIS
In normal cells, increased levels of miR-137 upon
oncogenic Ras triggers the p53 and Rb pathways
to promote cellular senescence. Inhibition of
KDM4A by miR-137 stabilizes p53, which in turn
stimulates miR-137 in a positive feedback loop.
The loss of miR-137 impairs OIS and cooperates
with Ras to bypass senescence, promoting
tumorigenesis. A dashed line is used to show that
miR-137 is a putative p53 target.CHD5, ASCL2, and PANX2 and also with KDM4A positively
modulated target PPIC. The levels of mRNAs forKDM4A in these
pancreatic cancer samples did not correlate with decreased
miR-137 levels. Although miR-137 might primarily regulate
KDM4A mRNA translation rather than mRNA degradation, it is
possible that there are other factors that preclude us from
observing KDM4A mRNA decay, such as elevated levels of
steady-state mRNAs. Moreover, we observed that the half-life
of theKDM4AmRNA in cycling fibroblasts is similar to senescent
fibroblasts induced by RasV12. This may be explained by the fact
that miRNA-mediated silencing is not solely the result of mRNA
decay, but also can be attributed to 50 cap-dependent translation
inhibition (Filipowicz and Sonenberg, 2015). Thus, the transcrip-
tional analysis of KDM4A downstream targets constituted a
more informative measure of KDM4A activity than KDM4A
mRNA levels.
It is important to consider endogenous miRNA expression
levels when studying miRNA-mediated translation inhibition.
miR-137 is annotated with 54 reads per million in the latest
version of miRBase database (http://www.mirbase.org/). Other
low-copy miRNAs, such as the miR-34 family (e.g., miR-34b an-
notatedwith 294 reads onmiRBase), have been shown to induce
senescence, and their loss of expression is a common feature in
cancer (Hermeking, 2010).
Despite relatively low amounts of miR-137, its >5-fold in-
crease observed in our RasV12-induced senescence model
(Figure S2A) reaches the same levels as miR-34. In addition, in-
hibition of miR-137 endogenous activity significantly impaired
the OIS response (Figure 4), and its expression was unde-
tected in pancreatic cancer cells. These results are consistent
with our findings that miR-137 is lost in pancreatic cancer, and
they reveal that miR-137 is a physiologically relevant mediator
of OIS.(E) PANC-1 cells described in (D) were fixed 8 days after transfection and stained for SA-b-gal. The mean perc
on the right panel are representative of two independent experiments with >100 cells per experiment. The sig
defined as **p < 0.01.
See also Figures S3 and S4.
Cell Reports 14, 1966–197miR-137 stimulates cellular senes-
cence by engaging the p16INK4A/pRb
and the ARF/p53 pathways indepen-
dently (Figures 2C and 3A). The partial
contribution of KDM4A in rescuing miR-
137-induced senescence (Figure 2D) im-
plies that there are other effectors ofmiR-137 involved in promoting senescence. miR-137 is known
to target cyclin-dependent kinase CDK6 and the Rho-GTPase
family member CDC42 (Liu et al., 2011; Zhu et al., 2013). CDK6
forms a complex with cyclin D to phosphorylate pRb and release
it from E2F-dependent genes, thus permitting S phase entry
(Choi and Anders, 2014). CDC42 controls cell-cycle progression
by stimulating cyclin D expression (Welsh et al., 2001), and it co-
operates with oncogenic Ras during transformation (Qiu et al.,
1997). Thus, miR-137 might regulate the p16INK4A/pRb pathway
at multiple levels, possibly through downregulation of CDK6 and
CDC42. On the other hand,miR-137 dampensKDM4A activity to
stimulate the p53 pathway in a positive feedback loop and also
triggers the p16INK4A/pRb pathway, which leads to cell-cycle ar-
rest and senescence (Figure 7).KDM4AmRNA is amain target of
miR-137 in the ARF/p53 pathway, since the concomitant resto-
ration of miR-137-resistant KDM4A in p16INK4A-depleted cells
leads to a complete bypass of senescence (Figure 3E).
miR-137 has been shown to modulate various cell-cycle reg-
ulators in Ras-dependent malignancies (Chen et al., 2012; Guo
et al., 2013; Liu et al., 2011; Zhang et al., 2015). Recently, miR-
137 was shown to regulate prostate and breast cancer cells’
proliferation by targeting a network of histone demethylases,
including KDM1A, KDM4A, KDM5, and KDM7A (Denis et al.,
2016; Nilsson et al., 2015), although the molecular mechanism
and physiological relevance of these observations remains to
be defined. Our findings provide the molecular evidence that
miR-137 regulation of KDM4A promotes cellular senescence
in pancreatic cancer, further supporting the tumor suppressor
activity of miR-137. We provide data that miR-137 not only re-
strains proliferation, but also is likely an intermediate that
bridges the gap between oncogenic stress signals and the
senescence response to ultimately counter cellular transforma-
tion (Figure 7).entage and SD of SA-b-gal-positive cells indicated
nificance was measured by the Student’s t test and
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Since miR-137 promotes cellular senescence and forestalls
tumorigenesis, it would be of importance to identify other mech-
anisms by which miR-137 might block transformation in vivo.
Recently, miRNAs also were found to participate in transcrip-
tional gene silencing, specifically in the case of proliferation-pro-
moting genes during senescence (Benhamed et al., 2012). Of
note, miR-137 has been found enriched in heterochromatin dur-
ing OIS (Benhamed et al., 2012), suggesting that miR-137 also
may regulate gene expression at the transcriptional level.
In view of the primary role of activated oncogenic Ras in hu-
man cancers, many strategies have been employed to inhibit
the Ras pathway (Samatar and Poulikakos, 2014). One current
approach involves targeting the downstream MAP kinase effec-
torsMEK and ERK (Sullivan and Flaherty, 2013). However, the in-
duction of senescence following Ras activation also has proven
to be an effective intrinsic tumor suppression mechanism (Braig
et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou
et al., 2005). As such our finding that miR-137 is an effector of
Ras during OIS provides additional insights for inducing tumor
suppressor networks in pancreatic cancer.
EXPERIMENTAL PROCEDURES
Western Blot Analysis
Cell were lysed in 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, and 1% Triton X-100 with Complete EDTA-free protease inhibitors
(Roche) and sonicated on ice three times 10 s. Cell extracts were separated
by SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad) for
immunoblotting. Primary antibodies used were the following: anti-a-tubulin
(B-5-1-2, Sigma, 1:50,000), anti-b-actin (A5441, Sigma, 1:5,000), anti-
KDM4A (75-189, clone N154/32, Neuromab, 1:1,000), and anti-p53 horse-
radish peroxidase (HRP) conjugated (HAF1355, R&D Systems, 1:5,000).
Goat anti-mouse or goat anti-rabbit IgG antibodies conjugated to HRP were
purchased from Sigma-Aldrich and detected using the enhanced chemilumi-
nescence (ECL) detection kit (DuPont).
Cell Culture, Retroviral Infections, and siRNA and miRNA
Transfections
Human fetal lung fibroblasts IMR90 (Coriell), HEK293T embryonic kidney
(ATCC), and osteosarcoma cells U2OS (ATCC) were cultured in DMEM, and
pancreatic cancer cell line PANC-1 (ATCC) was cultured in RPMI medium sup-
plementedwith 10% fetal bovine serum (FBS), 1mMsodium pyruvate, and an-
tibiotics. Retroviral infection procedures and vectors used (pLPC-puro and
pLPC-puro FLAG-KDM4A) were described previously (Mallette et al., 2012).
pLXSN and pLXSN-E6/E7 vectors were described previously (Mallette et al.,
2007). pLenti-III-miR-Off-Blank (miR-OFF-Ctrl) and pLenti-III-miR-Off-137
(miR-OFF-137) miRNA inhibitor lentiviral vectors were purchased from Applied
Biological Materials. The OHT-inducible RasV12 vector pLNCX2-neo (ER:
RasV12) was a kind gift from Dr. Masashi Narita. Cells expressing pLNCX2-
neo (ER:RasV12) were subcultured in phenol red-free DMEM medium and re-
newed with fresh OHT every 2–3 days. Transfection of plasmid DNA in
HEK293T cells was performed using Lipofectamine 2000 (Invitrogen), and
transfections in IMR90 fibroblasts were carried out using polyethylenimine
(PEI, Sigma) according to the manufacturer’s instructions. For miR-137-
induced senescence experiments, we performed two transfections with a
4-day interval to ensure high levels of miRNA mimic during the whole assay.
For DNA damage induction, cells were either left untreated or incubated with
500 nM doxorubicin for 16 hr. The list of siRNAs and miRNAs used is provided
in the Supplemental Experimental Procedures.
Luciferase Reporter Assay
HEK293T cells were transfected with 50 nM miRNA mimic. The day after, the
cells were co-transfected with the pMIR REPORTPhotinus pyralis (firefly) lucif-1976 Cell Reports 14, 1966–1978, March 1, 2016 ª2016 The Authorserase vector (Life Technologies) containing no 30 UTR as a transfection control
and the pCI-RL Renilla reniformis (Renilla) reporters. For the reporter assay in
IMR90 fibroblasts, the transfections were carried out using PEI. The next day,
cells were lysed in passive lysis buffer and assayed using the Dual-Luciferase
Reporter Assay System (Promega) according to the manufacturer’s instruc-
tions. Firefly and Renilla luminescence signals were read using the GloMax
20/20 luminometer (Promega) with an integration time of 10 s for each signal.
For the construction of the pCI-RLreporter vectors, 150 bp derived from the
KDM4AmRNA 30 UTR harboring wild-typeMREs (miR-137 Seed 1 (MRE1): re-
gion 4,209–4,358, seed sequence 50-GGG GTG GGA CTA GAG GGC AAT
AC-30; miR-137 Seed 2 (MRE2): region 4,359–4,508, seed sequence 50-CAT
CAC CTT GTC CTT AGC AAT AA-30 ) or mutated MREs were subcloned be-
tween the NheI and XbaI sites of the pCI-RL-5BoxB vector (Pillai et al.,
2004). For the mutated reporters, seed sequences were as follows: mutated
MRE1, 50-GGG GTG GGA CTA GAT TCG TTA TC; and mutated MRE2, 50-
CAT CAC CTT GTC CTT TCG TTA TA-30. The pCI-RL-5BoxB vector was a
kind gift from Dr. Mark R. Fabian.SA-b-gal Activity
Cells were stained for SA-b-gal activity as previously described (Mallette
et al., 2007). Briefly, IMR90 and PANC-1 cells were fixed with 0.5% glutar-
aldehyde in PBS for 15 min at room temperature. Fixed cells were washed
and stained at 37C. The staining solution was prepared fresh from potas-
sium ferrocyanide and potassium ferricyanide salt, X-Gal, and MgCl2 in
PBS (pH 6.0).Immunofluorescence
Immunostaining was performed essentially as described previously (Neault
et al., 2012). Briefly, cells were grown on glass coverslips, fixed with 4%
paraformaldehyde, and permeabilized with 0.2% Triton X-100. Cells were
then incubated with anti-PML (PG-M3, Santa Cruz Biotechnology, 1:200)
or anti g-H2AX antibody followed by staining with an Alexa Fluor 488-conju-
gated goat anti-mouse secondary antibody and DAPI staining to detect
nuclei. Coverslips were mounted with Immuno-Mount (Thermo Scientific).
Images were taken using Zeiss M1 and Olympus BX 53 fluorescence
microscopes.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
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